Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 0.55 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.55 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8048739 | 0.92 | FDPS (0.62) | FDPSGGPS1SMPD1AGTR1OPRM1 | |
| SCHEMBL8038146 | 0.91 | FDPS (0.47) | FDPSGGPS1SMPD1AGTR1OPRM1 | |
| SCHEMBL8052556 | 0.90 | FDPS (0.50) | FDPSGGPS1SMPD1AGTR1OPRM1 | |
| SCHEMBL8050321 | 0.82 | FDPS (0.61) | FDPSGGPS1PDE3A | |
| SCHEMBL8050542 | 0.81 | FDPS (0.52) | FDPSGGPS1SMPD1AGTR1OPRM1 | |
| SCHEMBL31105595 | 0.81 | FDPS (0.47) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL21361719 | 0.79 | FDPS (0.44) | FDPSGGPS1SMPD1PDE3A | |
| SCHEMBL4093004 | 0.78 | FDPS (0.86) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL8038317 | 0.77 | FDPS (0.58) | FDPSGGPS1PDE3A | |
| SCHEMBL14123895 | 0.77 | FDPS (0.69) | FDPSGGPS1SMPD1AGTR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0563096-B1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 2000-05-03 | — | — | EP | disclosed |
| US-5438048-A | Used for treatment of disorders related to metabolism of calcium and other bivalent metals; treats bone cancer, urolithiasis, rheumatoid arthritis, bone infection and bone degradation | LEIRAS OY (FI) | 1995-08-01 | — | — | US | disclosed |
| EP-0563096-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011267-A1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 1992-07-09 | — | — | WO | disclosed |